41827-90-1

Upstream product

• 697-82-5 2,3,5-trimethylphenol 
• 74-90-8 hydrogen cyanide 
• 4885-02-3 Dichloromethyl methyl ether 
• 54344-92-2 2,3,6-trimethyl-4-methoxy-benzaldehyde 
• 860510-71-0 3-chloro-2-hydroxy-4,6-dimethyl-benzyl alcohol 
• 90416-29-8 2-chloro-3,5,6-trimethylphenol 

Downstream Products

• 488-70-0 2,3,4,5-tetramethylphenol 
• 925441-95-8 4-(2-butynyloxy)-2,3,6-trimethylbenzaldehyde 
• 925441-96-9 4-(2-Pentynyloxy)-2,3,6-trimethylbenzaldehyde 
• 92864-93-2 1-acetoxy-4-acetoxymethyl-2,3,5-trimethyl-benzene 
• 925442-00-8 2,3,6-Trimethyl-4-[(trifluoromethyl)sulfonyl]benzaldehyde 
• 67992-68-1 E-4-(4-hydroxy-2,3,6-trimethylphenyl)-but-3-en-2-one 
• 925442-15-5 4-[(2,4-dichlorophenoxy)methyl]-2,3,6-trimethylbenzaldehyde 
• 925442-08-6 Methyl 4-(1,3-dioxan-2-yl)-2,3,5-trimethylbenzoate 
• 925442-09-7 [4-(1,3-Dioxan-2-yl)-2,3,5-trimethylphenyl]methanol 
• 925442-11-1 4-[(2-butynyloxy)methyl]2,3,6-trimethylbenzaldehyde 
• 925442-10-0 4-(Hydroxymethyl)-2,3,6-trimethylbenzaldehyde 
• 925442-01-9 methyl 4-formyl-2,3,5-trimethylbenzoate 
• 91799-53-0 2-bromo-3,4,5,6-tetramethyl-phenol 

Relevant academic research and scientific papers

Solid-phase synthesis: A linker for side-chain anchoring of arginine

A new linker based on a chroman system is described for the side-chain anchoring of Arg and other guanidine-containing molecules. The system is compatible with the Fmoc/tBu solid-phase strategy, because the release of the final product is achieved by treatment with TFA in the presence of scavengers.

o-Formylation of electron-rich phenols with dichloromethyl methyl ether and TiCl4

o-Formylation of electron-rich phenols is accomplished with dichloromethyl methyl ether and TiCl4. The reaction gives excellent yields, good regioselectivity, and does not leading to diformylation.

Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: Discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent

G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) is a free fatty acid (FFA) receptor that mediates FFA-amplified glucose-stimulated insulin secretion in pancreatic β-cells. We previously identified (2,3-dihydro-1-benzofuran-3-yl)acetic acid derivative 2 as a candidate, but it had relatively high lipophilicity. Adding a polar functional group on 2 yielded several compounds with lower lipophilicity and little effect on caspase-3/7 activity at 30 μM (a marker of toxicity in human HepG2 hepatocytes). Three optimized compounds showed promising pharmacokinetic profiles with good in vivo effects. Of these, compound 16 had the lowest lipophilicity. Metabolic analysis of 16 showed a long-acting PK profile due to high resistance to β-oxidation. Oral administration of 16 significantly reduced plasma glucose excursion and increased insulin secretion during an OGTT in type 2 diabetic rats. Compound 16 (TAK-875) is being evaluated in human clinical trials for the treatment of type 2 diabetes.

3,3′-dihydroxyisorenieratene, a natural carotenoid with superior antioxidant and photoprotective properties

(Figure Presented) The color of red smear cheeses arises from naturally occurring carotenoids like 3,3′-dihydroxyisorenieratene (1). This compound and its oxidation product 2, which have unusual phenolic and quinoid end groups, respectively, were synthesi